t
Disseminated via PRN on 23 September 2026
This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
23 September 2026
Acuity RM Group Plc
("Acuity", or "the Company")
Clarification of Warrant Terms
Acuity RM Group plc (AIM: ACRM), the software group specialising in the cybersecurity sector of the Governance, Risk and Compliance ("GRC") market, takes the opportunity to provide the following clarification in relation to the terms of warrants issued in connection with the Company's equity fundraisings undertaken during May, July and September 2025.
As disclosed in the Company's Annual Report and Accounts for the year ended 31 December 2025, a total of 87,607,143 warrants were issued in connection with those fundraisings, each entitling the holder to subscribe for one new ordinary share of 0.1 pence in the Company at an exercise price of 1.50 pence per share (collectively "the 2025 Warrants").
Certain announcements made by the Company in connection with the fundraisings stated that the relevant warrants were exercisable for a period of 12 months. The Company wishes to clarify that, under the terms of the warrant instruments, the 2025 Warrants are actually exercisable for a period of 18 months from the admission of the shares subscribed for in those fundraisings.
The 2025 Warrants have a clause, whereby if the closing mid-market price of the Company's ordinary shares is 2.00 pence or greater for five consecutive trading days within 12 months, the Company can elect to invoke an accelerator provision and give notice to holders of the 2025 Warrants requiring them to exercise their warrants or allow them to lapse.
The table below sets out details of the share warrants issued, and for completeness includes the warrants recently issued in connection with the July 2026 fundraising ("the 2026 Warrants"). The 2026 Warrants do not have an accelerator provision and have an exercise period of 12 months.
Holders of the 2025 Warrants who have any questions or wish to exercise their warrants should contact the Company. Holders of the 2026 Warrants who have any questions or wish to exercise their warrants should contact Neville Registrars (0121 585 1131 / [email protected]).
The warrants are not generally transferrable.
|
Admission of subscribed shares
|
Expiry of accelerator provision |
Expiry of warrants |
Exercise price of warrants |
Number of warrants |
|
23 May 2025 |
23 May 2026 |
23 November 2026 |
1.50p |
42,107,143 |
|
4 July 2025 |
4 July 2026 |
4 January 2027 |
1.50p |
10,500,000 |
|
26 September 2025 |
26 September 2026 |
26 March 2027 |
1.50p |
35,000,000 |
|
Total 2025 warrants
|
87,607,143 |
|||
|
9 July 2026 |
Not applicable |
8 July 2027 |
0.75p |
61,052,728 |
|
Total warrants |
148,659,871 |
|||
The terms of the warrant instruments themselves have not been amended and the rights of all warrant holders remain as originally constituted. The correct terms were disclosed in the Company's Annual Report and Accounts for the year ended 31 December 2025.
For further information please contact:
|
Acuity RM Group Plc Duncan Harper, Finance Director
|
020 3582 0566 www.acuityrmgroup.com
|
|
Zeus Capital (NOMAD & Joint Broker) Mike Coe / James Bavister
|
020 3829 5000 www.zeuscapital.co.uk
|
|
AlbR Capital (Joint Broker) Lucy Williams / Duncan Vasey
|
020 7469 0936 www.albrcapital.com |
|
Clear Capital Markets Limited (Joint Broker) Bob Roberts
|
020 3869 6080 www.clearcapitalmarkets.co.uk |
Note to Editors
Acuity RM Group plc (AIM: ACRM), is an established provider of risk management services. Its award-winning STREAM® software platform which collects and analyses data to improve business decisions and management used by clients operating in markets including government, defence, broadcasting, utilities, manufacturing and healthcare.
The Group is focused on delivering long term, sustainable growth in shareholder value from organic growth and complementary acquisitions.
The content and accuracy of news releases published on this site and/or distributed by PR Newswire or its partners are the sole responsibility of the originating company or organisation. Whilst every effort is made to ensure the accuracy of our services, such releases are not actively monitored or reviewed by PR Newswire or its partners and under no circumstances shall PR Newswire or its partners be liable for any loss or damage resulting from the use of such information. All information should be checked prior to publication.
